Disease Overview：Deep Vein Thrombosis（DVT）
Deep Vein Thrombosis (DVT) is a serious cardiovascular condition characterized by the formation of a thrombus within the deep venous system—most commonly in the lower limbs. Left untreated, DVT carries significant risk of pulmonary embolism, post-thrombotic syndrome, and chronic venous insufficiency. Diagnosis relies on clinical assessment, D-dimer testing, and confirmatory imaging such as compression ultrasonography or contrast-enhanced CT venography. Management encompasses anticoagulation therapy (e.g., direct oral anticoagulants or low-molecular-weight heparin), mechanical prophylaxis, and, in select cases, catheter-directed thrombolysis or inferior vena cava filter placement. Early intervention is critical to prevent morbidity and mortality.
China offers distinct advantages for DVT care: its leading cardiovascular centers—many accredited by JCI or ISO—employ advanced interventional radiology suites with real-time 3D vascular mapping, robotic-assisted thrombectomy platforms, and AI-integrated coagulation monitoring systems. Chinese vascular medicine specialists maintain high-volume experience in complex DVT cases, including extensive iliofemoral thrombosis and recurrent disease, with published success rates exceeding 92% for catheter-directed therapies. Treatment costs are typically 40–60% lower than in the US or Western Europe, without compromising evidence-based protocols or multidisciplinary follow-up. As a dedicated medical tourism agency, we facilitate seamless international patient journeys—curating top-tier hospitals, verifying physician credentials, providing itemized, transparent pricing in advance, and coordinating end-to-end support from visa assistance and interpreter services to post-discharge rehabilitation planning.
Deep Vein Thrombosis: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Deep Vein Thrombosis (DVT) — Cardiovascular Department
I. Non-Surgical / Conservative / Medication Management
*Target criteria:* Acute proximal DVT (calf, popliteal, femoral, iliac), low–moderate bleeding risk, no contraindications to anticoagulation.
- •Initial Anticoagulation (3–5 days)
- DOACs (rivaroxaban/apixaban): ¥120–¥260/day → $17–$36/day
- •Long-term Anticoagulation (3–6 months)
- Warfarin + INR monitoring: ¥180/month (drug) + ¥120/test × 8 tests → $25 + $134 = $159/month
- •Diagnostic Workup (per episode)
- D-dimer assay: ¥160 → $22 - Routine labs (CBC, renal/liver function, PT/INR): ¥240 → $33
II. Surgical / Procedural / Interventional Options
*Eligibility:* Massive iliofemoral DVT with limb threat, hemodynamic instability, or failure of medical therapy within 14 days; contraindication to anticoagulation *not* required for catheter-directed thrombolysis (CDT).
- •Catheter-Directed Thrombolysis (CDT)
- Preoperative workup (CT venography, ECG, troponin, coagulation panel): ¥1,120 → $156
- •Pharmacomechanical Thrombectomy (PMT)
- Preoperative workup (same as CDT): ¥1,120 → $156
- •Inferior Vena Cava (IVC) Filter Placement
- Filter implantation (including fluoroscopy, filter device): ¥15,800–¥22,400 → $2,200–$3,110 - Retrieval (if removable, within 3–6 months): ¥8,600–¥11,200 → $1,200–$1,560
III. Special / Complex Condition Management
- •Recurrent DVT or Cancer-Associated Thrombosis: LMWH monotherapy (dalteparin) — ¥5,200–¥7,800/month → $725–$1,085/month
- •Post-Thrombotic Syndrome (PTS) Management: Custom-fitted compression stockings (Class II/III): ¥800–¥2,200/pair → $111–$306; endovascular stenting (iliac vein): ¥26,000–¥38,000 → $3,620–$5,280
- •Chronic Thromboembolic Pulmonary Hypertension (CTEPH) referral: Requires right heart catheterization + pulmonary angiography (¥6,400 → $890) and multidisciplinary evaluation.
IV. Quick Selection Guide
- •<60 years, no comorbidities, mild–moderate DVT: Start DOACs + US/D-dimer → $462–$978 total first-month cost
- •≥75 years or high bleeding risk: LMWH bridging → warfarin + strict INR monitoring → $192–$225/month
- •Acute limb-threatening DVT (<72h onset): CDT preferred over PMT (lower device cost, comparable efficacy) → $2,726–$4,186 total procedural cost
- •Active malignancy: LMWH first-line → $725–$1,085/month, avoid DOACs if GI/GU cancer
- •Budget-constrained (<$500/month): Warfarin + monthly INR checks → $159/month, requires reliable follow-up access
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Deep Vein Thrombosis Medical Vacation Packages
Curated transparent all-inclusive packages combining Deep Vein Thrombosis treatment with China top medical destinations:
